Propranolol Reduces Portal Vein Diameter in Schistosomal Liver Disease with Portal Hypertension: A Prospective Cohort Study.

Simple item page
dc.contributor.affiliationDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
dc.contributor.affiliationDepartment of Internal Medicine, Tropical Gastroenterology and Nutritional Group, University of Zambia, Lusaka, Zambia.
dc.contributor.affiliationBlizard Institute, Barts and The London School of Medicine, Queen Mary University of London, London, United Kingdom.
dc.contributor.affiliationDepartment of Internal Medicine, University Teaching Hospital, Lusaka, Zambia.
dc.contributor.affiliationCentre for Infectious Disease Research in Zambia, Lusaka, Zambia.
dc.contributor.affiliationCIDRZ
dc.contributor.affiliationCentre for Infectious Disease Research in Zambia (CIDRZ)
dc.contributor.authorSinkala E
dc.contributor.authorVinikoor M
dc.contributor.authorZyambo K
dc.contributor.authorBesa E
dc.contributor.authorNsokolo B
dc.contributor.authorKelly P
dc.date.accessioned2025-05-23T11:41:12Z
dc.date.issued2020-Apr
dc.description.abstractHepatosplenic schistosomiasis (HSS) complicates portal hypertension, leading to life-threatening variceal bleeding. Variceal bleeding is associated with increased portal vein diameter (PVD). Beta-blockers prevent variceal bleeding. It is unclear whether beta-blockers such as propranolol can reduce PVD in HSS. We aimed to explore the effect of propranolol on PVD in HSS. A longitudinal study was conducted at the University Teaching Hospital, Zambia, as an extension of a clinical trial of rifaximin undertaken to test the hypothesis that rifaximin could reduce bacterial translocation in HSS. We randomized 85 adults to either rifaximin and standard care, or propranolol-based standard care only for 42 days. We then followed up all the patients on propranolol up to day 180. We used ultrasound to measure PVD at baseline and day 180. The primary outcome was reduction in PVD. Beta-blockade and splenic size reduction were secondary outcomes. Portal vein diameter reduced after 180 days of propranolol therapy from median 12 mm (interquartile range (IQR): 11-14) to median 10 mm (IQR: 9-13) (
dc.identifier.doi10.4269/ajtmh.19-0452
dc.identifier.urihttps://pubs.cidrz.org/handle/123456789/10427
dc.sourceThe American journal of tropical medicine and hygiene
dc.titlePropranolol Reduces Portal Vein Diameter in Schistosomal Liver Disease with Portal Hypertension: A Prospective Cohort Study.

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
article.pdf
Size:
825.06 KB
Format:
Adobe Portable Document Format
Download

Collections

Published